ABIO — ARCA biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $46.84m
- $9.41m
- 39
- 34
- 81
- 50
Annual cashflow statement for ARCA biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.48 | -9.74 | -19.3 | -9.93 | -5.34 |
| Depreciation | |||||
| Non-Cash Items | 0.222 | 0.128 | 0.572 | 0.655 | 0.782 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.441 | 1.88 | -0.028 | -1.66 | -0.472 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -4.8 | -7.72 | -18.8 | -10.9 | -5.01 |
| Capital Expenditures | -0.004 | -0.019 | -0.043 | -0.002 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | -0.004 | -0.019 | -0.043 | -0.002 | 0 |
| Financing Cash Flow Items | -0.372 | -2.03 | -0.977 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.56 | 48.5 | 23.1 | 0 | 0 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.75 | 40.7 | 4.29 | -10.9 | -5.01 |